Monocyte News and Research

RSS

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Experts to study how olive oil lowers the level of cytotoxicity in endothelial cells

Experts at Virgen del Rocío Hospital (Seville, Spain) have begun a study on pregnancy preeclampsia on a sample of 30 pregnant women with a view to demonstrating whether or not consumption of olive oil by this population group results in lower levels of cytotoxicity (for example, cholesterol) in endothelial cells (arterial wall cells).

19 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.

5 Nov 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

Inhaling carbon nanotubes can affect outer lining of the lungs

Carbon nanotubes are being considered for use in everything from sports equipment to medical applications, but a great deal remains unknown about whether these materials cause respiratory or other health problems.

26 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its anti-inflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

12 Oct 2009

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009.

9 Sep 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

New genetic mechanism to control body's fat-building process identified

At a time of alarming increases in obesity and associated diseases -- and fiery debates about the cost of health care -- a UCF research team has identified a new genetic mechanism that controls the body's fat-building process.

27 Aug 2009

Turmeric spice and vitamin D may help clear amyloid plaques found in Alzheimer's

UCLA scientists and colleagues from UC Riverside and the Human BioMolecular Research Institute have found that a form of vitamin D, together with a chemical found in turmeric spice called curcumin, may help stimulate the immune system to clear the brain of amyloid beta, which forms the plaques considered the hallmark of Alzheimer's disease.

15 Jul 2009

Microbial and maternal influences on allergic sensitization during childhood

When infected, the body has two types of immune defence to deploy - innate immunity and acquired immunity. In her dissertation, Shanie Saghafian Hedengren studies monocytes, a type of white blood corpuscles that are part of the innate immune system.

23 Jun 2009

Discovery of major new treatment target in diseased arteries

Removing a single protein prevents early damage in blood vessels from triggering a later-stage, frequently lethal complication of atherosclerosis, according to research published online today in the journal Nature Medicine. By eliminating the gene for a signaling protein called cyclophilin A (CypA) from a strain of mice, researchers were able to provide complete protection against abdominal aortic aneurysm (AAA).

11 May 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009

New insights into transcription factors in human cells

Bioinformatics researchers from UC San Diego just moved closer to unlocking the mystery of how human cells switch from "proliferation mode" to "specialization mode."

20 Apr 2009

Novel optical technique distinguishing single cells

Researchers at the University of Rochester have developed a novel optical technique that permits rapid analysis of single human immune cells using only light.

1 Apr 2009